Skip to main content
All lobbying clients

BIOTECHNOLOGY INNOVATION ORGANIZATION

Lobbying client · District of Columbia · filed 2025 to 2026

$14,160,000 Reported spend
45 Filings counted
6 Outside firms hired
89 Bills named

Spend is reported income plus in-house expenses across 45 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 7 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

 Who filed for this client 7

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings top 30 of 89
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
    15 filings
  • H.R. 946
    ORPHAN Cures Act
    11 filings
  • S. 932
    Give Kids a Chance Act of 2025
    10 filings
  • H.R. 1
    One Big Beautiful Bill Act
    7 filings
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    7 filings
  • H.R. 1672
    Maintaining Investments in New Innovation Act
    7 filings
  • S. 1096
    Preserve Access to Affordable Generics and Biosimilars Act
    6 filings
  • S. 1097
    Interagency Patent Coordination and Improvement Act of 2025
    6 filings
  • S. 527
    Prescription Pricing for the People Act of 2025
    6 filings
  • H.R. 3152
    Patent Eligibility Restoration Act of 2025
    5 filings
  • H.R. 3160
    PREVAIL Act
    5 filings
  • S. 1041
    Affordable Prescriptions for Patients Act
    5 filings
  • S. 1095
    Stop STALLING Act
    5 filings
  • S. 1546
    Patent Eligibility Restoration Act of 2025
    5 filings
  • S. 1553
    PREVAIL Act
    5 filings
  • S. 2276
    ETHIC Act
    5 filings
  • S. 2658
    Medication Affordability and Patent Integrity Act
    5 filings
  • S. 43
    Skinny Labels, Big Savings Act
    5 filings
  • S. 526
    Pharmacy Benefit Manager Transparency Act of 2025
    5 filings
  • S. 864
    HELP Copays Act
    5 filings
  • H.R. 5256
    340B ACCESS Act
    4 filings
  • H.R. 6423
    HELP Copays Act
    4 filings
  • H.R. 6485
    Skinny Labels, Big Savings Act
    4 filings
  • S. 705
    Innovation in Pediatric Drugs Act of 2025
    4 filings
  • S. 832
    EPIC Act of 2025
    4 filings
  • H.R. 5391
    Protecting Patient Access to Cancer and Complex Therapies Act
    3 filings
  • S. 2764
    Protecting Patient Access to Cancer and Complex Therapies Act of 2023
    3 filings
  • H.R. 3169
    SBIR/STTR Reauthorization Act of 2025
    3 filings
  • H.R. 3269
    ETHIC Act
    3 filings
  • H.R. 3323
    Helping Startups Continue To Grow Act
    3 filings
 Reported by year 2 years
  • 2026 $7,470,000 18 filings
  • 2025 $6,690,000 27 filings
 Issues lobbied 17
 Agencies and chambers lobbied 25
  • HOUSE OF REPRESENTATIVES 40
  • SENATE 40
  • Natl Security Council (NSC) 12
  • Centers For Medicare and Medicaid Services (CMS) 11
  • Commerce, Dept of (DOC) 11
  • Office of Management & Budget (OMB) 11
  • U.S. Trade Representative (USTR) 10
  • Food & Drug Administration (FDA) 9
  • Natl Economic Council (NEC) 9
  • Executive Office of the President (EOP) 8
  • State, Dept of (DOS) 8
  • Health & Human Services, Dept of (HHS) 7
  • Patent & Trademark Office (PTO) 7
  • Treasury, Dept of 5
  • White House Office 5
  • Natl Institutes of Health (NIH) 3
  • Small Business Administration (SBA) 3
  • Federal Trade Commission (FTC) 2
  • Office of Science & Technology Policy (OSTP) 2
  • Office of the Vice President of the United States 2
  • Agriculture, Dept of (USDA) 1
  • Council of Economic Advisers (CEA) 1
  • Energy, Dept of 1
  • Justice, Dept of (DOJ) 1
  • Securities & Exchange Commission (SEC) 1
 Recent filings 45 total
Q3 report
BIOTECHNOLOGY INNOVATION ORGANIZATION
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $2,560,000 expenses · posted Oct 20, 2026
View →
Q3 report
AVOQ, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View →
Q3 report
BGR GOVERNMENT AFFAIRS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
VALCOUR LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
AKIN GUMP STRAUSS HAUER & FELD
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
DLA PIPER LLP (US)
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 19, 2026
View →
Q2 report
BIOTECHNOLOGY INNOVATION ORGANIZATION
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $2,360,000 expenses · posted Jul 20, 2026
View →
Q2 report
AVOQ, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $80,000 income · posted Jul 20, 2026
View →
Q2 report
BGR GOVERNMENT AFFAIRS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
VALCOUR LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
AKIN GUMP STRAUSS HAUER & FELD
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
DLA PIPER LLP (US)
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 17, 2026
View →
Q1 report
AVOQ, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 20, 2026
View →
Q1 report
VALCOUR LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
BIOTECHNOLOGY INNOVATION ORGANIZATION
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $1,620,000 expenses · posted Apr 20, 2026
View →
Q1 report
BGR GOVERNMENT AFFAIRS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026
View →
Q1 report
AKIN GUMP STRAUSS HAUER & FELD
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026
View →
Q1 report
DLA PIPER LLP (US)
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 20, 2026
View →
Q4 report
AVOQ, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $80,000 income · posted Jan 20, 2026
View →
Q4 report
BIOTECHNOLOGY INNOVATION ORGANIZATION
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $1,510,000 expenses · posted Jan 20, 2026
View →

Showing the 20 most recent of 45 filings. Search the explorer for "BIOTECHNOLOGY INNOVATION ORGANIZATION".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem